SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Personalized Virology Initiative study group

doi:10.1016/S2666-5247(21)00068-9

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Personalized Virology Initiative study group

Research output: Contribution to journal › Letter › peer-review

215 Scopus citations

Original language	English
Pages (from-to)	e283-e284
Journal	The Lancet Microbe
Volume	2
Issue number	7
DOIs	https://doi.org/10.1016/S2666-5247(21)00068-9
State	Published - Jul 2021

Access to Document

10.1016/S2666-5247(21)00068-9

Cite this

@article{8a526ac4182940378d5902087509902a,

title = "SARS-CoV-2 spike E484K mutation reduces antibody neutralisation",

author = "{Personalized Virology Initiative study group} and Sonia Jangra and Chengjin Ye and Raveen Rathnasinghe and Daniel Stadlbauer and Hala Alshammary and Amoako, {Angela A.} and Awawda, {Mahmoud H.} and Beach, {Katherine F.} and Berm{\'u}dez-Gonz{\'a}lez, {Maria C.} and Chernet, {Rachel L.} and Eaker, {Lily Q.} and Ferreri, {Emily D.} and Floda, {Daniel L.} and Gleason, {Charles R.} and Giulio Kleiner and Denise Jurczyszak and Matthews, {Julia C.} and Mendez, {Wanni A.} and Mulder, {Lubbertus C.F.} and Russo, {Kayla T.} and Salimbangon, {Ashley Beathrese T.} and Miti Saksena and Shin, {Amber S.} and Sominsky, {Levy A.} and Komal Srivastava and Florian Krammer and Viviana Simon and Luis Martinez-Sobrido and Adolfo Garc{\'i}a-Sastre and Michael Schotsaert",

note = "Funding Information: SJ and CY contributed equally. The Personalized Virology Initiative study group members and their affiliations, declarations of interests, and acknowledgments are listed in the appendix. This research was partly funded by the Center for Research for Influenza Pathogenesis, a Center of Excellence for Influenza Research and Surveillance supported by the National Institute of Allergy and Infectious Diseases (contract number HHSN272201400008C), by the National Cancer Institute grant U54CA260560, by the JPB Foundation and the Open Philanthropy Project (research grant 2020–215611 [5384], and by anonymous donors to AG-S. Work on SARS-CoV-2 in the Krammer and Simon laboratories was funded by the Collaborative Influenza Vaccine Innovation Centers' contract number 75N93019C00051. Research in the Martinez-Sobrido laboratory was partly funded by the New York Influenza Center of Excellence, a member of the National Institute of Allergy and Infectious Diseases, and was also partially funded by the National Institutes of Health, the Department of Health and Human Services, and the Centers of Excellence for Influenza Research and Surveillance (contract number HHSN272201400005C, New York Influenza Center of Excellence). Funding sources had no role in the study design, in the collection, analysis, and interpretation of the data, in the writing of the Correspondence, and in the decision to submit the Correspondence for publication. The Garc{\'i}a-Sastre laboratory has received research support from Pfizer, Senhwa Biosciences, and 7Hills Pharma. AG-S has consulting agreements for 7Hills Pharma, Avimex, and Esperovax involving cash, and Vivaldi Biosciences, Contrafect, Accurius, and Vaxalto involving stock. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and Newcastle disease virus-based SARS-CoV-2 vaccines which list FK as co-inventor. DS and VS are also listed on the serological assay patent application as co-inventors. FK has consulted for Merck and Pfizer (before 2020), and is currently consulting for Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. All other authors declare no competing interests. ",

year = "2021",

month = jul,

doi = "10.1016/S2666-5247(21)00068-9",

language = "English",

volume = "2",

pages = "e283--e284",

journal = "The Lancet Microbe",

issn = "2666-5247",

publisher = "Elsevier Ltd.",

number = "7",

}

TY - JOUR

T1 - SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

AU - Personalized Virology Initiative study group

AU - Jangra, Sonia

AU - Ye, Chengjin

AU - Rathnasinghe, Raveen

AU - Stadlbauer, Daniel

AU - Alshammary, Hala

AU - Amoako, Angela A.

AU - Awawda, Mahmoud H.

AU - Beach, Katherine F.

AU - Bermúdez-González, Maria C.

AU - Chernet, Rachel L.

AU - Eaker, Lily Q.

AU - Ferreri, Emily D.

AU - Floda, Daniel L.

AU - Gleason, Charles R.

AU - Kleiner, Giulio

AU - Jurczyszak, Denise

AU - Matthews, Julia C.

AU - Mendez, Wanni A.

AU - Mulder, Lubbertus C.F.

AU - Russo, Kayla T.

AU - Salimbangon, Ashley Beathrese T.

AU - Saksena, Miti

AU - Shin, Amber S.

AU - Sominsky, Levy A.

AU - Srivastava, Komal

AU - Krammer, Florian

AU - Simon, Viviana

AU - Martinez-Sobrido, Luis

AU - García-Sastre, Adolfo

AU - Schotsaert, Michael

N1 - Funding Information: SJ and CY contributed equally. The Personalized Virology Initiative study group members and their affiliations, declarations of interests, and acknowledgments are listed in the appendix. This research was partly funded by the Center for Research for Influenza Pathogenesis, a Center of Excellence for Influenza Research and Surveillance supported by the National Institute of Allergy and Infectious Diseases (contract number HHSN272201400008C), by the National Cancer Institute grant U54CA260560, by the JPB Foundation and the Open Philanthropy Project (research grant 2020–215611 [5384], and by anonymous donors to AG-S. Work on SARS-CoV-2 in the Krammer and Simon laboratories was funded by the Collaborative Influenza Vaccine Innovation Centers' contract number 75N93019C00051. Research in the Martinez-Sobrido laboratory was partly funded by the New York Influenza Center of Excellence, a member of the National Institute of Allergy and Infectious Diseases, and was also partially funded by the National Institutes of Health, the Department of Health and Human Services, and the Centers of Excellence for Influenza Research and Surveillance (contract number HHSN272201400005C, New York Influenza Center of Excellence). Funding sources had no role in the study design, in the collection, analysis, and interpretation of the data, in the writing of the Correspondence, and in the decision to submit the Correspondence for publication. The García-Sastre laboratory has received research support from Pfizer, Senhwa Biosciences, and 7Hills Pharma. AG-S has consulting agreements for 7Hills Pharma, Avimex, and Esperovax involving cash, and Vivaldi Biosciences, Contrafect, Accurius, and Vaxalto involving stock. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and Newcastle disease virus-based SARS-CoV-2 vaccines which list FK as co-inventor. DS and VS are also listed on the serological assay patent application as co-inventors. FK has consulted for Merck and Pfizer (before 2020), and is currently consulting for Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. All other authors declare no competing interests.

PY - 2021/7

Y1 - 2021/7

UR - http://www.scopus.com/inward/record.url?scp=85104952416&partnerID=8YFLogxK

U2 - 10.1016/S2666-5247(21)00068-9

DO - 10.1016/S2666-5247(21)00068-9

M3 - Letter

AN - SCOPUS:85104952416

SN - 2666-5247

VL - 2

SP - e283-e284

JO - The Lancet Microbe

JF - The Lancet Microbe

IS - 7

ER -